Welcome to the 2021 IGCS Meeting Program Scheduling
The meeting will officially run on Central European Time (Rome time-zone, GMT+2)
To convert the meeting times to your local time Click Here
Industry Hall 1
Session Type
Industry Symposia
Room
Industry Hall 1
Date
09/02/2021
Session Description
How Cemiplimab is EMPOWERING change in the management of recurrent cervix cancer- Supported by IGCS
Session Description:
Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free survival and objective response rate, compared to chemotherapy. Improvements in overall survival were seen in the overall population and both squamous cell carcinoma and adenocarcinoma subgroups. It is important to explore the significance of this trial, its applicability to clinical practice and management of any adverse events.
Industry Symposia
How Cemiplimab is EMPOWERING change in the management of recurrent cervix cancer (ID 1139)
Lecture Time
04:45 PM - 04:45 PM
Industry Symposia
Supported by IGCS (ID 1140)
Lecture Time
04:45 PM - 04:45 PM
Industry Symposia
Landscape in Cervix Cancer and Why empower was needed as a trial (ID 1141)
Industry Symposia
Study design details and outcomes (ID 1142)
Industry Symposia
Quality of Life, managing toxicities etc. (ID 1143)
Industry Symposia